Ronny Hermansen, CEO of Genetic Analysis, comments:
"The fourth quarter reflects continued execution of our long-term growth strategy, with progress in both commercial expansion and product development. We are advancing collaborations with industry partners, further strengthening the position of GA-map® technology in microbiome-related clinical applications.

As microbiome diagnostics gain broader clinical adoption, our focus remains on delivering reliable, standardized and scalable testing solutions to laboratories and healthcare providers worldwide.

I am proud of the team's achievements during the year and confident that we are well positioned to build further momentum in 2026."

*This includes a positive impact from a pre-payment received from a customer.

Definitions:
Equity ratio:                                  Shareholder's equity as a proportion of total assets.
Earnings per share:                    Profit/Loss for the period divided by an average number of shares.
Constant currency:                    This year's sales converted to NOK by using last year's exchange rates.

Revenues and Gross margin

Sales revenue (excluding grants) reached an all-time high of NOK 6.4 million in Q4 2025, an increase of 9.8% at constant currency and 2.9% at actual currency compared to Q4 2024.

For the full year 2025, sales revenue totaled NOK 16.7 million, up 9.6% at constant currency and 5.2% at actual currency versus 2024.

Gross margin declined from 83% to 68% primarily due to:

• New US import duties (NOK 0.56 million)
• Negative currency effect (NOK 0.43 million)

Adjusted for these impacts, gross margin would have been approximately 79%, in line with 2024 levels.

Core product sales (GA-map® tests) grew strongly:

• Up 36.5% in Q4 at constant currency (29.4% at actual rates)
• Up 16.4% year-to-date at constant currency (12.2% at actual rates)

EBITDA

EBITDA in Q4 2025 totaled NOK - 2.1 million ( NOK -0.8 million) and was negatively affected by:

• New U.S. import duties: NOK 0.56 million
• Currency fluctuations: NOK 0.43 million

Cash Flow and Liquidity

• Cash flow from operations: NOK 2.4 million for 2025 (vs. -11.6 million in 2024)
• Cash and cash equivalents: NOK 24.0 million on 31 December 2025 compared to NOK 13.4 million on 31 December 2024. This includes a positive impact from a pre-payment received from a major customer.

Highlights during and after Q4 2025

• On 17 November, Genetic Analysis AS announced the completion of the biomarker panel development in its ongoing IBD Precision Dx project. This marked a major milestone in the project, with GA now progressing to the final validation phase and completion of the software development.
• On 12 February, Genetic Analysis AS announced that its patent application CA2980637 had been allowed for grant in Canada.  The patent entitled "METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS" covers the Company's unique algorithm incorporated in the GA-map® technology for profiling gut microbiota. GA has an active patent strategy covering all major geographical markets and has previously announced approval in EU, China and other countries for this patent.
• On 19 February, Genetic Analysis AS announced that its patent application US2017/0369941 had been allowed for grant by the United States Patent and Trademark Office (USPTO). The patent, entitled "METHOD FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP'S", strengthens the protection of GA's proprietary diagnostic technology. GA maintains an active patent strategy covering all major geographical markets and has previously announced approval in the EU and other countries for this patent.